These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 39036070)

  • 1. A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications.
    Wang S; Zhang W; Yang B; Zhang X; Fang J; Rui H; Chen Z; Gu J; Chen Z; Xu J
    Antib Ther; 2024 Jul; 7(3):189-198. PubMed ID: 39036070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
    Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
    MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies.
    Loh HP; Mahfut FB; Chen SW; Huang Y; Huo J; Zhang W; Lam KP; Xu S; Yang Y
    MAbs; 2023; 15(1):2231129. PubMed ID: 37403264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developability considerations for bispecific and multispecific antibodies.
    Amash A; Volkers G; Farber P; Griffin D; Davison KS; Goodman A; Tonikian R; Yamniuk A; Barnhart B; Jacobs T
    MAbs; 2024; 16(1):2394229. PubMed ID: 39189686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Developability and Disposition Profiles of Bispecific Antibodies: A Case Study with Two Molecules.
    Datta-Mannan A; Brown R; Key S; Cain P; Feng Y
    Antibodies (Basel); 2021 Dec; 11(1):. PubMed ID: 35076469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors.
    Root AR; Guntas G; Katragadda M; Apgar JR; Narula J; Chang CS; Hanscom S; McKenna M; Wade J; Meade C; Ma W; Guo Y; Liu Y; Duan W; Hendershot C; King AC; Zhang Y; Sousa E; Tam A; Benard S; Yang H; Kelleher K; Jin F; Piche-Nicholas N; Keating SE; Narciandi F; Lawrence-Henderson R; Arai M; Stochaj WR; Svenson K; Mosyak L; Lam K; Francis C; Marquette K; Wroblewska L; Zhu HL; Sheehan AD; LaVallie ER; D'Antona AM; Betts A; King L; Rosfjord E; Cunningham O; Lin L; Sapra P; Tchistiakova L; Mathur D; Bloom L
    MAbs; 2021; 13(1):1850395. PubMed ID: 33459147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
    Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
    MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ion Mobility-Mass Spectrometry and Collision-Induced Unfolding of Designed Bispecific Antibody Therapeutics.
    Villafuerte-Vega RC; Li HW; Slaney TR; Chennamsetty N; Chen G; Tao L; Ruotolo BT
    Anal Chem; 2023 May; 95(17):6962-6970. PubMed ID: 37067470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics.
    Zhang W; Wang H; Feng N; Li Y; Gu J; Wang Z
    Antib Ther; 2023 Jan; 6(1):13-29. PubMed ID: 36683767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds.
    Yu L; Huang N; Ge L; Sun H; Fu Y; Liu C; Wang J
    J Biol Eng; 2021 Jun; 15(1):18. PubMed ID: 34187511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation on environmental factors contributing to bispecific antibody stability and the reversal of self-associated aggregates.
    Ingavat N; Dzulkiflie N; Liew JM; Wang X; Leong E; Loh HP; Ng SK; Yang Y; Zhang W
    Bioresour Bioprocess; 2024 Aug; 11(1):82. PubMed ID: 39177850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biology drives the discovery of bispecific antibodies as innovative therapeutics.
    Nie S; Wang Z; Moscoso-Castro M; D'Souza P; Lei C; Xu J; Gu J
    Antib Ther; 2020 Jan; 3(1):18-62. PubMed ID: 33928225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highlights of Antibody Engineering and Therapeutics 2019 in San Diego, USA: Bispecific Antibody Design and Clinical Applications.
    Zhu Y; Shen R; Hao R; Wang S; Ho M
    Antib Ther; 2020 Apr; 3(2):146-154. PubMed ID: 32671329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blueprint for antibody biologics developability.
    Mieczkowski C; Zhang X; Lee D; Nguyen K; Lv W; Wang Y; Zhang Y; Way J; Gries JM
    MAbs; 2023; 15(1):2185924. PubMed ID: 36880643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Generation of Murine Bispecific Antibodies Using FAST-Ig
    Koga H; Kuroi H; Hirano R; Hirayama H; Nabuchi Y; Kuramochi T
    Antibodies (Basel); 2024 Jan; 13(1):. PubMed ID: 38247567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.
    Li H; Er Saw P; Song E
    Cell Mol Immunol; 2020 May; 17(5):451-461. PubMed ID: 32313210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 Fab arm exchange and "bispecific" monoclonal antibody formation.
    Debaene F; Wagner-Rousset E; Colas O; Ayoub D; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
    Anal Chem; 2013 Oct; 85(20):9785-92. PubMed ID: 24007193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early engineering approaches to improve peptide developability and manufacturability.
    Furman JL; Chiu M; Hunter MJ
    AAPS J; 2015 Jan; 17(1):111-20. PubMed ID: 25338742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Buffers on Colloidal Property and Aggregation Propensities of a Bispecific Antibody.
    Majumder S; Wang W; Alphonse Ignatius A
    J Pharm Sci; 2019 Mar; 108(3):1139-1147. PubMed ID: 30391414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.
    Chen IJ; Cheng YA; Ho KW; Lin WW; Cheng KW; Lu YC; Hsieh YC; Huang CC; Chuang CH; Chen FM; Su YC; Roffler SR; Cheng TL
    Acta Biomater; 2020 Jul; 111():386-397. PubMed ID: 32417267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.